Table 1.
Risk factors associated with severe radiodermatitis.
| Factors | All patients (n = 9) | Severe group (n = 3) | Non-severe group (n = 6) | P value | |
|---|---|---|---|---|---|
| Patient-related factors |
Age (years) | 57 (52–82) | 70 (57–82) | 55.5 (52–77) | 0.167 |
| Sex | |||||
| Male | 7 (77.8%) | 3 (100.0%) | 4 (66.7%) | 0.500 | |
| Female | 2 (22.2%) | 0 (0.0%) | 2 (33.3%) | ||
| BMI (kg/m2) | 21.09 (16.22–29.43) | 21.09 (20.40–28.67) | 21.43 (16.22–24.43) | 0.714 | |
| Cancer type | |||||
| Larynx | 2 (22.2%) | 1 (33.3%) | 1 (16.7%) | 0.810 | |
| Oropharynx | 2 (22.2%) | 0 (0.0%) | 2 (33.3%) | ||
| Hypopharynx | 4 (44.4%) | 2 (66.7%) | 2 (33.3%) | ||
| Tongue | 1 (11.1%) | 0 (0.0%) | 1 (16.7%) | ||
| Disease stage | |||||
| I | 1 (11.1%) | 0 (0.0%) | 1 (16.7%) | 0.290 | |
| II | 2 (22.2%) | 1 (33.3%) | 1 (16.7%) | ||
| III | 3 (33.3%) | 0 (0.0%) | 3 (50.0%) | ||
| IV | 3 (33.3%) | 2 (66.7%) | 1 (16.7%) | ||
| Smoker | |||||
| Previous | 8 (88.9%) | 3 (100.0%) | 5 (83.3%) | 1.000 | |
| Never | 1 (11.1%) | 0 (0.0%) | 1 (16.7%) | ||
| Alb (g/L) | 38 (30–43) | 35 (30–40) | 40 (37–43) | 0.167 | |
| Hb (g/L) |
119 (95–157) |
117 (95–137) |
132 (105–157) |
0.262 |
|
| Radiotherapy factors | Total dose | ||||
| 69.96 Gy | 8 (88.9%) | 3 (100.0%) | 5 (83.3%) | 1.000 | |
| 60.00 Gy | 1 (11.1%) | 0 (0.0%) | 1 (16.7%) | ||
| Fractional dose | |||||
| 2.12 Gy | 8 (88.9%) | 3 (100.0%) | 5 (83.3%) | 1.000 | |
| 2.00 Gy | 1 (11.1%) | 0 (0.0%) | 1 (16.7%) | ||
| Radiosensitizer | |||||
| Cisplatin | 8 (88.9%) | 2 (66.7%) | 6 (100.0%) | 0.333 | |
| Cetuximab | 1 (11.1%) | 1 (33.3%) | 0 (0.0%) | ||
| Topical corticosteroids | |||||
| Use | 7 (77.8%) | 3 (100.0%) | 4 (66.7%) | 0.500 | |
| Non-use | 2 (22.2%) | 0 (0.0%) | 2 (33.3%) | ||
Continuous variables were compared using the Mann–Whitney U test and are presented as the median (range). Nominal variables were compared using the Fisher's exact test and are presented as n (%). BMI, body mass index; Alb, albumin; Hb, hemoglobin.